Procedural sedation and analgesia in children is now widely practised in many emergency departments internationally. In this article, we address the general principles, indications, guidelines, medications, adverse events and future research in paediatric procedural sedation and analgesia in the Emergency Department.
InTRoduCTIon
Procedural sedation and analgesia is the use of sedative, analgesia and dissociative drugs to provide anxiolysis, analgesia, sedation and motor control during painful or unpleasant diagnostic and therapeutic procedures 1 . Emergency physicians over the world, for the last 2 decades, have developed specialised skills in managing patients requiring sedation for procedures within the emergency settings, particularly in young paediatric patients. It is now a component of the core curriculum for emergency medicine residency programmes.
In the Children's Emergency of the KK Women's and Children's Hospital, procedural sedation has been practised since 1998, and averages 100 cases per month for surgical procedures performed in the Emergency Department (ED). Many minor surgical procedures that were previously done in the operating theatre are now performed in the ED, bringing cost savings to the patients and the healthcare economics of the country. In a retrospective review of the first 500 paediatric patients who have undergone procedural sedation by Ng et al, 96% of the patients were discharged home after the procedure, with 3.6% admitted either because of the failure of the surgical procedures or because of their clinical condition (e.g. laceration with head injury requiring 24-hour observation). Only one child (0.2%) was admitted possibly as a result of the adverse reaction of ketamine 2 .
In this article, we address the general principles, indications, guidelines, medications, adverse events and future research in paediatric procedural sedation and analgesia in the ED.
dEfInITIonS
Minimal Sedation refers to a drug-induced state during which patients respond normally to verbal commands. Although cognitive function and coordination may be impaired, ventilation and cardiovascular functions remain unaffected. This is sometimes referred to as "anxiolysis" 3 .
Moderate Sedation (formerly referred to as "conscious sedation") is a drug-induced depression of consciousness, during which the patient responds purposefully to either verbal commands alone, or accompanied by light tactile stimulation. Cardiovascular function is generally maintained. In addition, no interventions are required to maintain the patency of the airway and spontaneous ventilation is adequate 3 .
Deep Sedation/Analgesia is a drug-induced depression of consciousness during which patients cannot be easily aroused but respond purposefully following repeated or painful stimulation. Cardiovascular function is usually maintained. However, assistance may be necessary in maintaining the patency of the airway and spontaneous ventilation may be inadequate 3 .
General Anaesthesia is a drug-induced loss of consciousness, during which patients are not aroused, even by painful stimulation. There is usually a loss in the ability to independently maintain a patent airway. Positive pressure ventilation may be necessary because of depressed spontaneous ventilation, or due to drug-induced depression of neuromuscular function. Cardiovascular function may be impaired 3 .
Dissociative sedation has been described as a trance-like cataleptic state characterised by profound analgesia and amnesia, with retention of airway protective reflexes, spontaneous respiration and cardiopulmonary stability. The terms of minimal, moderate, deep and general anaesthesia sedation refer to forms of sedation that do not apply to dissociative sedation 4 .
It is important to remember that the degrees of sedation occur on a continuum. This continuum can be extremely variable and is dependent on individual responses, age, health status and the combination of drugs used.
GuIdElInES
Internationally, major clinical guidelines have been issued and revised since the 1980s. The guidelines published by the American Academy of Pediatrics (AAP) 5 , the American College of Emergency Physicians (ACEP) 6 and the American Society of Anaesthesiologist (ASA) are some of the most widely disseminated ones. These guidelines help to set standards and ensure patient safety in the practice of paediatric procedural sedation. In Singapore, since the instituting of accreditation of healthcare organisations by Joint Commission International (JCI), it is important for healthcare institutions whose physicians practise sedation to have standard policy and procedure (P&P) 7 .
The general principles of procedural sedation include pre-sedation assessment, continuous monitoring during the procedure and during recovery post procedure, which mirrors guiding principles in anaesthesia practices 1 . Sedation of children is different from adults. The ability of the child to cooperate during the procedure depends on the chronological age and the developmental stage of the child. Thus, very often, sedation is administered to control behaviour for the safe completion of the surgical procedure.
PRE-SEdATIon ASSESSmEnT
Physician providing the sedation need to ensure that a current history and physical examination is done and documented to assess the suitability of the patient as candidate for sedation.
Candidate
Patients who are in ASA classes I and II (Table 1 , overleaf ) are considered to be suitable candidates for mild, moderate, deep and dissociative sedation. Children in ASA classes III and IV are at increased risk of adverse events if subjected to sedation, especially moderate or deep sedations 5 . Surgical procedures for these patients may be best performed in the operating theatre with anaesthetists administering the sedation or anaesthesia.
The airway should also be examined for abnormalities that might impair airway management or limit neck mobility (e.g., severe obesity, short neck, small mandible, obstructive tonsils, large tongue, and trismus).
Patients with known significant cardiovascular conditions (such as cyanotic heart disease, congestive cardiac failure), when administered sedatives, may developed hypotension. Children with respiratory conditions, such as chronic lung disease, active upper respiratory tract infection are at risk of respiratory complications during sedation.
In patients with hepatic or renal impairment, the delayed metabolism and excretion of drugs need to be taken into consideration prior to sedation.
Personnel
A physician who is accredited to performed sedation by the hospital, and trained at least in basic cardiac life support (BCLS). Other personnel (Emergency Physicians) who are trained in advanced cardiac life support skills should be readily available when need arise 1 . A nurse who is trained in BCLS and sedation is needed to monitor the patient before, during and after the procedure, and assist in documentation. There should be another nurse to assist the doctor in performing the surgical procedure.
Indications
Common surgical (therapeutic) procedures performed under sedation in the ED include toilet and suturing, manipulation and reduction of fractures and dislocations, incision and drainage of abscesses, foreign body removal, dental procedures and burns dressing. Sedation is also performed for diagnostic procedures such as computerised tomography (CT) imaging, mainly in the noncooperative patient, who is otherwise not in any cardio-respiratory compromise.
Contraindications
An essential component of the pre-sedation assessment is to assess for any contraindications to sedation in the ED. Extra caution and general anaesthesia or anaesthetist supervised sedation should be considered for patients with medical conditions that predisposed them to the risks of adverse reactions (Table 2) 7 .
fasting There is no evidence that a specific fasting duration is necessary for sedation, especially for dissociative sedation with ketamine, whereby airway reflexes are maintained 8 . The ACEP in the clinical policy on paediatric procedural sedation stated that procedural sedation may be safely administered to paediatric patients in the ED who have had recent oral intake (Level B recommendations) 6 .
However, the AAP which adopts the ASA fasting guidelines recommends a fasting time of 6 hours for solids (including formula milk), 4 hours for breast milk and 2 hours for clear fluids before elective procedures 5 . With regards to emergency procedures, the physician must always balance the possible risks of sedating non-fasted patients with the benefits and necessity for completing the procedure. Although a rare occurrence, pulmonary aspiration may occur if the child regurgitates and cannot protect his/her airway, particularly during deep sedation. When proper fasting has not been ensured, the lightest effective sedation should be used. The use of agents, such as ketamine, with less risk of depressing protective airway reflexes is preferred 9 .
In our institution, we have adopted a fasting time of 3 hours from the last solids for minimal and moderate sedation, including dissociative sedation. This is to allow emergency surgical procedures to be performed without much delay, and at the same time, avoids unnecessary risks of aspiration due to non-fasted conditions. For deep sedations, the ASA fasting guidelines apply 7 .
documentations (Pre-procedural)
For moderate and deep sedation, informed consent by the parents or caregivers should be taken prior to the procedure. They should be given information and instructions regarding the sedation (objectives and risks) and post-sedation care at home. A set of normal vital signs (HR, RR, SpO2 and BP) are documented prior to sedation. Fasting times, contraindications to sedation, any past medical history especially if currently on medications and allergies should be checked.
Certain herbal medicines such as Echinacea, may alter drug pharmacokinetics through inhibition of the cytochrome P450 system, resulting in prolonged drug effect and altered (increased or decreased) blood drug concentrations 10 .
Equipment and mechanical monitoring
An emergency resuscitation trolley/cart must be immediately accessible, containing the necessary age and size-appropriate paediatric equipment and drugs for resuscitation when airway or circulatory complications arise (Table 3) . A cardiac defibrillator with size-appropriate pads should also be part of the resuscitation equipment. There should also be 2 oxygen points for supplemental oxygen delivery and ventilation. Suction apparatus are essential for airway management 1, 5, 7 . dextrose / 0.45% saline)  Cardiac defibrillator (with size-appropriate pads)  Resuscitation trolley (cart) with resuscitation drugs and reversal agents. other Considerations For moderate sedation using intramuscular, oral, or inhalational (nitrous oxide) administration, intravenous access is not mandatory. For deep sedation, intravenous access is necessary, so as to allow resuscitation if adverse events occur 1, 7 . If other forms of restraints are needed, such as papoose boards, it is important to ensure that they do not obstruct the airway or restrict chest expansion 5 .
InTRA-PRoCEduRAl monIToRInG And doCumEnTATIon
The patient's chart contains a time-based record that includes name, route, site, time, dosage and any adverse effects. Before the sedation, a "timeout" should be done to confirm the patient's name, procedure to be performed, and site of the procedure 5 . All sedative medication doses and mode of administration should be carefully checked and calculated (per kg weight) before administration. For inhalational sedative agent (nitrous oxide), the inspired concentration of oxygen and sedative agent administered and duration shall be documented.
During the procedure, there should be continuous observation and monitoring of the patient for airway patency, respiratory rate, heart rate, oxygen saturation, level of consciousness, and occurrence of any adverse reaction. Intermittent documentation of blood pressure every 5-10 minutes in deep sedation is needed. Continuous monitoring of ECG is required for patients with significant cardiovascular disease or when arrhythmias are anticipated 7 .
Routine supplemental oxygen during sedation has not been shown to decrease respiratory adverse events. Studies have shown that supplemental oxygen, may delay the recognition of impaired ventilation efforts, unless there was presence of continuous capnography 8, 11, 12 . A controlled trial of supplemental oxygen for procedural sedation and analgesia by Deitch et al 13 noted similar rates of hypoxia and respiratory depression in moderately sedated patients with and without supplemental oxygen, showing no apparent advantage in the use of supplemental oxygen. However, if hypoxia should occur, oxygen should be immediately available.
PoST-PRoCEduRAl monIToRInG And doCumEnTATIon
After moderate or deep sedation, the child should be monitored in a suitably equipped recovery room within the ED (has suction apparatus, 100% oxygen delivery system, resuscitation trolley). Continuous monitoring of the vital signs, as during the procedure, should continue till the child meets discharge criteria (Table 4) .
mEdICATIonS uSEd foR PRoCEduRAl SEdATIon In ChIldREn (TABlE 5) Ketamine
Ketamine is generally regarded as a dissociative agent, which produces a trance-like cataleptic state -characterised by profound analgesia and amnesia. Protective airway reflexes, spontaneous respiration and cardiopulmonary stability are usually well maintained, as long as doses are kept within recommended doses. It can be administered either intravenously or intramuscularly 7 . The initial IV dose is 1mg/kg, followed by 0.25mg/kg every 2 minutes (to achieve 1mg/kg) as indicated, and up to a maximum IV dose of 5mg/kg. The IM dose is 2-4mg/kg, with the repeat dose given at half of the initial IM dose (i.e. 1-2mg/kg), and up to a maximum IM dose of 10mg/kg.
Ketamine is effective as an agent for procedural sedation in the ED. It has also demonstrated a generally good safety profile 2, 7, [14] [15] [16] . The main side effects of ketamine include enhanced sympathomimetic Table 4 . Discharge criteria.
 Able to independently maintain an airway  Oxygen saturation >95% in room air, or equivalent to baseline levels prior to sedation  Stable cardiovascular status  Easily aroused, able to talk (if age appropriate), or is at pre-procedural baseline level of consciousness  Able to move / walk with minimal assistance  A responsible adult, must be given written post-sedation instructions and to escort the patient home  If a reversal agent has been given, monitoring must continue for a minimum of 2 hours before discharge Table 5 . Summary chart for medications for procedural sedation in children. Table 6 .
There is contention regarding the addition of a benzodiazepine (usually midazolam) to reduce the incidence of emergence reaction/ recovery agitation. In adults, the incidence of hallucinatory reactions appears to be highly variable (0-30%) 2 . However, in the paediatric age group, the incidence appears to be minimal and the reaction mild. Also, the addition of midazolam as an adjunct to ketamine for procedural sedation for children in the ED does not decrease the incidence of emergent reactions. As such, whilst benzodiazepine prophylaxis should be considered in adults, it should not be routine in children 7, 2, 14, 17, 18 .
Adjunctive anti-cholinergics have been commonly co-administered during ketamine sedation in the ED in children, to counter the induced hyper salivation, with the aim of decreasing the occurrence of adverse respiratory events, including laryngospasm. Atropine is commonly administered as an anti-sialogogue (dose at 0.01mg/kg, minimum 0.1 mg, maximum 0.5mg) 7 . However, opinions remain divided.
Some studies cite a positive benefit of adjunctive atropine in significantly reducing the incidence of hypersalivation 19 . Others, however, report that even with the omission of atropine, excessive salivation is uncommon and that associated airway complications are rare 20 . Interestingly, adjunctive atropine was found to significantly decrease the risk of post-procedural vomiting [20] [21] , though it did not significantly decrease airway or respiratory events.
midazolam/fentanyl
Benzodiazepines are beneficial for procedural sedation for their effects as in anxiolysis, sedation and amnesia. A short-acting benzodiazepine, such as midazolam, is generally preferred, with a rapid onset of sedation (about 1-5 minutes if administered intravenously) 7 . The initial intravenous dose is 0.05-0.1mg/kg, with repeat dosing at 0.05mg/kg and up to a maximum dose of 0.15mg/kg. The primary adverse effects of midazolam are respiratory depression, paradoxical excitement and hypotension, worsened when co-administered with other respiratory depressants. The effects of midazolam may be reversed by flumazenil 14 .
Fentanyl is an opiate, favoured for its rapid onset of action, short duration of action and its benefits in providing analgesia and sedation. It has a faster onset of action but less cardio-depressive effects when compared to morphine. Fentanyl Table 6 . Contraindications to the use of ketamine for procedural sedation. can be administered via the intravenous (IV) or intramuscular (IM) route. The initial dose (IV/ IM) is 1mcg/kg, with repeat dosing at 0.5mcg / kg, and up to a maximum dose of 3mcg/ kg. The primary adverse effects of fentanyl are respiratory depression, nausea, vomiting and chest wall rigidity (especially with higher doses or rapid administration). The effects of fentanyl may be reversed by naloxone 7, 14, 22 .
Contraindications
Fentanyl and midazolam are effective agents for sedation and analgesia in the paediatric population, with a high level of efficacy (ranging from 91-100%). The use of opiates and benzodiazepines together is widely reported to produce synergism of the desired analgesic and sedative effects. However, the combination of fentanyl and midazolam appears to result in a greater risk of respiratory depression, even though these events are generally mild, requiring mainly oxygen or stimulation, with the rare need for ventilation support 7, 14 .
Drug interactions may also occur with midazolam. Drugs (such as erythromycin, ranitidine, fluconazole, verapamil) known to inhibit cytochrome P3A4 (CYP3A4) increases the serum levels of midazolam. Other drugs (such as carbamazepine, phenytoin and rifampicin) stimulate CYP3A4 and decrease the level of midazolam 7 .
morphine Morphine acts by binding to the opioid receptors and alters perception of pain. It is primarily an analgesic, with poor sedative properties, and is useful in supplementing sedation during painful procedures. It can be administered parenterally (intravenous or intramuscular) or orally, with an onset of 5-10 minutes intravenously, and 30-50 minutes intramuscularly. For infants between the ages of 1-6 months, the recommended dose is 0.025-0.1 mg/kg. For those above 6 months old, the dose is 0.05-0.1 mg/kg. The repeat dose is half the initial dose, with the maximum dose not exceeding 0.1 mg/kg. The common adverse effects are nausea, vomiting, respiratory depression, hypotension, sedation and pruritus. Naloxone is given as antidote in over-sedation in incremental doses of 0.01mg/kg, repeated every 2-3 minutes as needed 7 .
Etomidate
Etomidate is a carboxylated imidazole sedativehypnotic agent, with no analgesic properties. It has a rapid onset of action (1 minute) and a short duration of action (4 to 15 minutes). It produces rapid induction, with minimal cardiovascular and respiratory effects, and minimal histamine release 14 .
Adverse effects of etomidate include injection site pain and transient myoclonus 14 . Etomidate has been implicated in the lowering of the seizure threshold in patients with a history of focal seizures, and hence should be used with care. In addition, haemodynamic changes in blood pressure and heart rate have also been documented with large doses or rapid administration of etomidate. The recommended dosing is 0.1mg/kg, followed by 0.05mg/kg every 3 to 5 minutes and up to a maximum dose of 10mg 23 .
There have been recent concerns about the potential of etomidate to inhibit cortisol production -especially in critically ill children 24 . However, the clinical significance of the decrease in cortisol production remains controversial -in otherwise well children undergoing procedural sedation in the ED, a single dose of etomidate would not usually produce clinically significant adrenal insufficiency 25 .
Propofol
Propofol is a highly lipid-soluble alkyl phenol sedative agent. It has been used alone for procedural sedation as well as painless diagnostic studies such as MRI or CT scans. It has a rapid onset of action (about 40 seconds), a short duration of action (1-3 minutes) and hence, swift emergence and recovery 26 .
For short procedures, propofol is often administered as a slow bolus (recommended paediatric dosing 1 mg/kg), followed by additional doses (0.5mg/kg every 3 minutes) as necessary 27 . For longer procedures, following the intravenous bolus, a continuous infusion (2-4 mg/kg/hour) of propofol may be used to maintain sedation 28 .
As propofol is classified as a pure sedative, for painful procedures, it is often combined with an opiate agent for optimal analgesic effect. The use of propofol with opiate agents is effective and generally safe for procedural sedation in the ED 26, 29 . However, as it is associated with a rapid deepening of a sedation level to that of general anaesthesia,
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Proceedings of Singapore Healthcare  Volume 19  Number 2  2010 close monitoring is necessary in view of its potential side effects of hypoventilation and hypoxia, which may require head-repositioning, supplemental oxygen as well as bag-valve-mask ventilation. 30 As such, its use has been limited, in some centres, to administration within the operating theatre or by the anaesthesiologist only.
Of note, there has also been concern about the "propofol infusion syndrome" -characterised by bradycardia, asystole, severe metabolic acidosis, lipidemia, hepatomegaly, rhabdomyolysisin critically-ill children on long-term propofol infusions in the intensive care unit 31 . Again, this is of controversial significance in otherwise well children undergoing procedural sedation with propofol in the ED.
nitrous oxide
Nitrous oxide (N 2 O) is a relatively weak dissociative anaesthetic gas, which can provide anxiolysis, analgesia and amnesia. It is usually administered as Entonox (pre-mix of N 2 O 50% and oxygen 50%) or continuously (inspired concentration of N 2 O 50-70%). It is important to note that nitrous oxide should never be administered without oxygen 7 . Nitrous oxide can be used with concurrent local anaesthesia for safe and effective procedural sedation in healthy children undergoing painful procedures 6 .
The onset of action is usually within 2-5 minutes of inhalation, and lasts for the duration that it is administered. Post-procedurally, oxygen (100%) should be administered for about 3-5 minutes to prevent diffusion hypoxia. When used in concentrations greater than 50% or in combination with other sedatives (e.g. chloral hydrate, midazolam etc.), the likelihood of moderate / deep sedation increases. Hence the attending physician must be aware of the possibility and institute appropriate measures and monitoring. A gas-scavenging system should be used for protection of healthcare providers when administering nitrous oxide 6, 7 .
Contraindications include children with increased risk of airway loss (infants less than 1 year old, patients with acute respiratory infections, asthma exacerbation, or a history of difficult airway), patients with increased intracranial pressure (closed head injury with loss of consciousness or altered mental state), patients with pulmonary hypertension as well other underlying conditions with a risk of expansion of air-filled closed space (e.g. pneumothorax, abdominal distension or bowel obstruction, decompression sickness or airembolism, middle ear disease, recent neurosurgical interventions in the last 7 days etc) 7 . Side effects are generally mild, with nausea, vomiting, dizziness and light-headedness. Aspiration may occur in patients who become deeply sedated 7 .
Chloral hydrate
Chloral hydrate is a sedative hypnotic agent, which can be administered per-orally or perrectally. Therapeutic levels can be achieved after 30-60 minutes post-administration. The duration of action is expected to be 4-8 hours, although it has been known to produce residual effects for up to 24 hours. The recommended dosing for infants less than 6 months of age is 50mg/kg (maximum dose 500mg). For infants and children 6 months and older, the dosing is 50-75mg/kg, with a maximum dose of 1,000mg for those between 6 months to 3 years of age, and 1,500mg for those more than 3 years old. Repeat dosing, at 25mg/kg, can be administered for all age groups, as long as the total combined dose does not exceed the recommended maximum dose. In children older than 48 months, chloral hydrate may not be as efficacious 6 .
The common adverse effects include gastrointestinal irritation, nausea, vomiting and diarrhoea. Chloral hydrate, like all other sedative hypnotic agents, has the potential for central nervous system depression and suppression of respiratory activity 6 . In addition; large doses of chloral hydrate have been reported to produce hypotension as well as cardiac arrhythmias. As such, caution is needed in the neonatal age-group and patients with pre-existing cardiac disease. In addition, if there is failure to sedate with an appropriate dose of chloral hydrate, one should avoid the addition of other sedatives for fear of respiratory depression 7 .
Appropriate dosing, proper patient monitoring as well as physician training, can go a long way, in the use of chloral hydrate as an effective procedural sedation agent for paediatric patients for painless diagnostic studies or examination 6, 7 .
As it can be seen, there are various options in the use of medications for procedural sedation. Hospital policies on procedural sedation, as well as the physician's familiarity with the use of particular agents, will affect the pattern of usage of these medications in the ED. For procedures which may be protracted, such as repair of cosmetically significant facial lacerations, hand injuries and nailbed injuries, as well as manipulation and reduction of fractures, the use of IM ketamine has served us well. Ketamine can be administered via the IV route for brief procedures less than 15 minutes. For the above procedures, in cases where ketamine may be contraindicated, a combination of IV midazolam and fentanyl can be used as an alternative. Nitrous oxide can provide adequate analgesia and anxiolysis for very brief procedures, such as minor fracture manipulation, reduction of dislocations (e.g. phalanges, patella) as well as intravenous cannulation for very anxious children. The use of chloral hydrate in our practice is very much limited to painless diagnostic studies (e.g. CT imaging), or in combination with a topical anaesthetic for the repair of non-cosmetically significant lacerations.
AdvERSE EvEnTS duRInG SEdATIon
The 32, 33 . Thirty thousand and thirty seven sedations/anaesthesia were encountered. The sedations were performed by anaesthetists, emergency physicians, intensivists, paediatricians, radiologists, and advanced practice nurses. Fifty point one percent of the patients were given propofol, 27.1% midazolam, 13.6% ketamine, 13.2% pentobarbital and 8% fentanyl. There were no deaths, but cardiopulmonary resuscitation was required for 1 patient. Oxygen desaturations below 90% for >30 seconds occurred 157 times per 10,000 sedations. Approximately 1 in 400 procedures is associated with stridor, laryngospasm, wheezing or apnoea. One in every 200 sedations required airway and ventilation interventions ranging from bag-and mask ventilations to oral airways to emergency intubations. Though vomiting occurred in 47.2 per 10,000 encounters, only 1 patient was documented to have aspirated in that entire series. Failed sedation occurred 89 times per 10,000 sedations, whereas prolonged sedation/ recovery occurred 36 per 10,000 sedations. The overall incidence of complications was 5.3%.
In another recently published large scale meta-analysis by Green SM et al, 34 on specifically paediatric ketamine sedations in the EDs, 32 reports comprising 8,282 ketamine sedations were included. The overall incidence of airway and respiratory adverse events was 3.9%, including 0.3% laryngospasm, and 0.8% apnoea. No children required intubation or received paralytics in the management of these airway events. This contrast with the rate of 0.5% of sedations requiring some form of airway interventions, when other sedative agents were included, as mentioned in the study by the Pediatric Sedation Research Consortium. Predictors of significant airway adverse events identified were: younger age less than 2 (OR 2.00, 95% CI 1.47-2.72), aged 13 and above (OR 2.72; 95%CI 1.97-3.75), high intravenous dose (initial dose >2.5mg/kg or total dose >5mg/kg), and the use of co-administered anticholinergics or benzodiazepines.
In the same study (8, 282 ketamine sedations) but analysing other complications of emesis and recovery agitation, the authors reported 8.4% of emesis and 1.4% of clinically significant recovery agitation. Early adolescence had been identified as the peak age for ketamine associated emesis, whereas recovery agitation is not age related to a clinically important degree 35 . The authors also found no benefit of co-administered benzodiazepine in reducing recovery agitation.
The results of the studies do not simply reassure providers that sedation of children is of low risk, but rather they help to define core competencies (airway management and resuscitations skills) required to deliver this care 36 .
RESCuE mEASuRES foR Common AdvERSE EvEnTS 7
Airway obstruction This is common, and may occur in levels above moderate sedation. When a child under sedation desaturates, check for airway obstruction by using airway maneuvers, such as head tilt, chin lift and jaw thrust. Suction the oral secretions especially in young children. Airway adjuncts (such as oropharyngeal or nasopharyngeal airways) may be used if appropriate. 
Respiratory depression

Allergic Reactions
Common signs of allergic reactions include flushing, tachycardia, urticaria with or without hypotension. Administer intravenous adrenaline 1: 10,000 at 0.1ml /kg, followed by diphenhydramine (IV/IM 1mg/kg) and hydrocortisone IV 5mg/kg when anaphylaxis occurs.
Emesis and Aspiration
Recent food intake, excessive crying (aerophagia) and bowel obstruction are risk factors for emesis and aspiration. If a nasogastric tube is present before sedation, aspirate the stomach prior to procedure.
fuTuRE RESEARCh
The future of procedural sedation and analgesia will focus on enhancing training, safety and effectiveness. Safety issues involve defining the most appropriate monitoring for the different levels of sedation, and establishing adverse event registries to monitor safety and standards of practice. Efficacy studies will determine which drugs are most effective for a specific procedure and age of patient 1 .
One current limitation to evidence based procedural sedation research is the inability to aggregate results from existing studies, due to varied terminology to describe the same adverse events and outcomes, as investigators do not have a standardised set of definitions and reporting guidelines to follow. A panel of experts from 2 national collaborative pediatric emergency medicine research networks (Paediatric Emergency Research Canada and Pediatric Emergency Care Applied Research network) developed consensusbased recommendations for standardising terminology and reporting adverse events for pediatric sedations in the EDs 37 . This "Quebec Guidelines" if internationally adopted, will create a uniform reporting mechanism for future studies.
Another aspect of sedation practice that has not been studied much is the effectiveness of training of ED physicians as sedation providers. The recent use of human patient simulators in the training of sedation practice has generated significant interest. Keidan et al uses a unique paediatric simulation model to demonstrate that supplemental oxygen compromises the use of pulse oximetry for detection of apnoea and hypoventilation during sedation 38 . This study showed how human simulators have the advantage of offering a platform in which identical scenarios can be presented to a myriad of different providers with variation of a specific variable over time 36 . This allows objective assessment of performance.
Recent rodent and monkey research has shown that ketamine can induce accelerated programmed nerve cell death (apoptosis) when administered in high doses, for prolonged period of time, or both. The Food and Drug Administration and National Institute of Health in the United States have started investigations due to concern about similar neurotoxicity in human therapeutic use.
However, these studies are very controversial in that the animals experiencing ketamine induced apoptosis are equivalent to human mid-term fetus and extremely premature neonate in terms of neurological development, well before the age of typical clinical use. Also, multiple animal studies have shown that approximately 40mg/kg is the threshold at which neurotoxicity becomes marked relative to baseline. The therapeutic dose use in ED is far lower than that. This controversial question may be best resolved through long-term large scale epidemiological study of children receiving ketamine. Until the results of such studies are available, there is insufficient evidence to alter current clinical practice 39 .
